Locanabio will close up shop by the end of the year as a tough market for biotechs claims another company that had been working on developing RNA medicines for rare diseases such as Duchenne muscular dystrophy (DMD).
Locanabio presents preclinical data on improved vectorized snRNA platform for exon skipping for the potential treatment of DMD at WMS2023
SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative...
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative...
Locanabio to report preclinical data from snRNA exon skipping program in DMD and Cas13d-mediated C9orf72 ALS program SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines...
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
Biotech startup Locanabio has laid off 30% of its workforce, portending a limited scope going forward for the gene therapy developer, backed with more than $150 million since its 2019 unveiling.
Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with severe neuromuscular and neurodegenerative...
Locanabio, Inc., an RNA-targeting gene therapy company, today announced the appointment of Kat Lange as chief financial officer. In this role, Ms. Lange will be a key member of the executive leadership team and will lead Locanabio's financial operations, planning and strategy.
Locanabio picked up two key executives Tuesday, with CRISPR Therapeutics' John Leonard as chief scientific officer and Audentes' Edward Conner as CMO.